Long-term disease control by endobiliary radiofrequency ablation in localized extrahepatic cholangiocarcinoma: a first case report.

Clin J Gastroenterol

Department of Gastroenterology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.

Published: December 2023

An 84-year-old woman with cerebrovascular disease, dementia, and chronic kidney disease developed jaundice because of localized extrahepatic cholangiocarcinoma (eCCA) at the lower bile duct. Aggressive treatment, including surgery and chemotherapy, was difficult because of the underlying disease; therefore, only metal stent placement with endobiliary radiofrequency ablation (RFA) was performed. Subsequently, six additional RFA sessions were performed 12, 16, 24, 27, 33, and 36 months after the initial RFA using the same settings as the first RFA session. All these procedures were performed for tumor ingrowth. Computed tomography performed 42 months after the initial procedure revealed no stent with stricture resolution and no other metastatic lesion. Thereafter, no recurrence or adverse events have been observed with persisting stent-free status until the reporting of this study (72 months after the initial procedure). This is the first report of a stent-free status and long-term survival in a patient with localized eCCA that was achieved using only endobiliary RFA without any other anti-tumor treatment. Although several problems and issues associated with endobiliary RFA remain unelucidated, it may be a useful therapeutic option for early and localized eCCA in poor surgical candidates.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-023-01845-3DOI Listing

Publication Analysis

Top Keywords

endobiliary radiofrequency
8
radiofrequency ablation
8
localized extrahepatic
8
extrahepatic cholangiocarcinoma
8
initial procedure
8
stent-free status
8
localized ecca
8
endobiliary rfa
8
rfa
6
long-term disease
4

Similar Publications

Percutaneous transhepatic cholangiography: An effective option for endo-biliary radiofrequency ablation before stent insertion in unresectable biliary cancer?

World J Clin Cases

October 2024

Academic Department of Gastroenterology, Medical School of the National and Kapodistrian University of Athens, "Laiko" General Hospital, Athens 11527, Greece.

Biliary cancer is a highly aggressive disease that is typically diagnosed at advanced stages when surgical removal is no longer an option. In these cases, palliative care and mechanical widening of the blocked biliary system are preferred. The insertion of a stent is often necessary to prevent the recurrence of blockages caused by cancer progression.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the safety and effectiveness of percutaneous endobiliary radiofrequency ablation (EB-RFA) for treating stubborn benign biliary strictures in 15 patients who had unsuccessful traditional treatments.
  • Results showed a 100% technical success rate and an 87% clinical success rate after a median follow-up of 17 months, indicating significant improvement in patients’ conditions.
  • The findings suggest that EB-RFA is a promising option for these strictures, though more extensive studies are needed for more conclusive evidence.
View Article and Find Full Text PDF

Introduction: The role of endo-biliary radio-frequency ablation (EB-RFA) in treating malignant biliary strictures remains a subject of controversy. This study aims to assess the efficacy and safety of EB-RFA in conjunction with self-expandable metal stents (SEMS) compared to SEMS alone.

Methods: This single-center prospective pragmatic comparative study, conducted between June 2021 and November 2022, involved 23 patients undergoing EB-RFA plus SEMS and 48 patients undergoing SEMS for unresectable malignant hilar obstruction.

View Article and Find Full Text PDF

Percutaneous endobiliary radiofrequency ablation and stent placement for unresectable malignant biliary obstruction: a propensity score matching retrospective study.

BMC Gastroenterol

August 2024

Department of Interventional Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan 2nd Road, Guangzhou, 510080, China.

Background: Whether endobiliary radiofrequency ablation (EB-RFA) changes the standard role of stent placement in treating unresectable malignant biliary obstruction (MBO) remains unclear. The aim of this study is to compare percutaneous EB-RFA and metal stent placement (RFA-Stent) with metal stent placement alone (Stent) in treating unresectable MBO using a propensity score matching (PSM) analysis.

Methods: From June 2013 to June 2018, clinical data from 163 patients with malignant biliary obstruction who underwent percutaneous RFA-Stent or stenting alone were retrospectively analyzed using a nearest-neighbor algorithm to one-to-one PSM analysis to compare primary and secondary stent patency (PSP, SSP), overall survival (OS) and complications between the two groups.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the safety and effectiveness of combining endobiliary radiofrequency ablation (EB-RFA) with percutaneous transhepatic cholangiodrainage (PTCD) for managing patients with unresectable malignant obstructive jaundice.
  • Results showed significant decreases in the total and direct bilirubin levels within a week post-procedure, indicating improved jaundice control, although other liver function markers showed no significant changes.
  • Complications were minimal, with some patients experiencing biliary bleeding and pancreatitis, but there were no serious complications or deaths, leading to a median survival of 4 months for the patients involved.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!